Lumos Pharma, Inc.
LUMO
$-0.06
Change (1 day)
$4.55
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
P/B ratio for Lumos Pharma, Inc. (LUMO)
P/B ratio as of 2023: 0.95
According to Lumos Pharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.95. At the end of 2022 the company had a P/B ratio of 0.51.
P/B ratio history for Lumos Pharma, Inc. from 2008 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.95 |
| 2022 | 0.51 |
| 2021 | 0.65 |
| 2020 | 2.08 |
| 2019 | 0.00 |
| 2018 | 0.05 |
| 2017 | 0.19 |
| 2016 | 0.26 |
| 2015 | 0.59 |
| 2014 | 0.60 |
| 2013 | 1.06 |
| 2012 | 1.61 |
| 2011 | 0.13 |
| 2010 | -0.21 |
| 2009 | -0.26 |
| 2008 | -0.33 |